CHICAGO — Teclistamab continued to demonstrate durable efficacy for patients with relapsed or refractory multiple myeloma, according to results from the phase 1/phase 2 MajesTEC-1 trial.
Updated results from the trial — presented at ASCO Annual Meeting and published simultaneously in The New England Journal of Medicine — showed a median duration of response of more than 18 months among heavily pretreated patients.
Teclistamab (JNJ-64007957, Janssen) — an investigational bispecific antibody that binds B-cell maturation antigen (BCMA) and CD3 — is designed to provide
